Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential - Takeaways - MDSpire

Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential

  • By

  • Qionghui Wu

  • Shanlin Chen

  • Xiaodong Xie

  • Xinli Feng

  • Zhenchang Zhang

  • Gang Su

  • June 18, 2026

  • 0 min

Share

  • 1

    RAC1 is identified as a key prognostic biomarker in glioblastoma (GBM), with significant implications for patient survival and treatment strategies.

  • 2

    Lasso-Cox regression analysis confirmed RAC1's prognostic relevance, showing a hazard ratio of 2.61 for overall survival in GBM patients.

  • 3

    Single-cell RNA sequencing revealed RAC1 enrichment in neural progenitor cell-like tumor states, indicating its role in immune evasion.

  • 4

    RAC1-high GBM cells exhibited activation of the PI3K-AKT-mTOR and IFN-gamma pathways, correlating with resistance to immune checkpoint inhibitors.

  • 5

    Palbociclib demonstrated dose-dependent inhibition of GBM cell viability, suggesting potential as a therapeutic strategy targeting RAC1.

Original Source(s)

Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential

  • by Qionghui Wu, Shanlin Chen, Xiaodong Xie, Xinli Feng, Zhenchang Zhang, Gang Su

  • June 18, 2026

Related Content

Malignant transformation of uterine serosal endometriosis to clear cell carcinoma in a postmenopausal patient: a rare case report

Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma

Homologous recombination pathway alterations in basal-like breast cancer